Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections

Lung

Volumn 194, Issue 4, 2016, Pages 687-697

  Koatz, Ana M ^a   Coe, Noemí A ^b   Cicerán, Alberto ^c   Alter, Adriana J ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

^c FAVALORO UNIVERSITY   (Argentina)

^d Hospital Maria Curie   (Argentina)

Author keywords

Asthma; Bacterial lysate; COPD; Exacerbation; OM 85; Re infection; Respiratory tract infection; Rhinitis

Indexed keywords

BACTERIUM LYSATE; SECRETORY IMMUNOGLOBULIN; BRONCHO-VAXOM; CELL EXTRACT; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BLOOD SAMPLING; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SCREENING; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OPEN STUDY; OXYGEN SATURATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; BLOOD; COMPLICATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; SALIVA; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ASTHMA; CELL EXTRACTS; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RESPIRATORY TRACT INFECTIONS; RHINITIS, ALLERGIC; SALIVA; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; SYMPTOM FLARE UP; YOUNG ADULT;

EID: 84979052786     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-016-9880-5     Document Type: Article

References (42)

1. Anand VK (2004) Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 193:3–5
2. Bosch AA, Biesbroek G, Trzcinski K et al (2013) Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog 9:e1003057
3. Chang LH, Rivera MP (2013) Respiratory diseases: meeting the challenges of screening, prevention, and treatment. N C Med J 74:385–392
4. Schaad U, Principi N (2012) The management of recurrent respiratory tract infections in children. Eur Infect Dis 6:111–115
5. West JV (2002) Acute upper airway infections. Br Med Bull 61:215–230
6. Yui I, Fujino M, Sawada A et al (2014) Novel clinical features of recurrent human respiratory syncytial virus infections. J Med Virol 86:1629–1638
7. Finney LJ, Ritchie A, Pollard E et al (2014) Lower airway colonization and inflammatory response in COPD: a focus on. Int J Chron Obstruct Pulmon Dis 9:1119–1132
8. Rantala A, Jaakkola JJ, Jaakkola MS (2013) Respiratory infections in adults with atopic disease and IgE antibodies to common aeroallergens. PLoS ONE 8:e68582
9. Kay AB (2001) Allergy and allergic diseases. First of two parts. N Engl J Med 344:30–37
10. Pauwels RA, Buist AS, Ma P et al (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: national Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46:798–825
11. Chen C, Deng Y, Chen H et al (2014) Decreased concentration of IL-35 in plasma of patients with asthma and COPD. Asian Pac J Allergy Immunol 32:211–217
12. Al-Mohanna F, Parhar R, Kawaasi A et al (1993) Inhibition of neutrophil functions by human immunoglobulin E. J Allergy Clin Immunol 92:757–766
13. Cirillo I, Marseglia G, Klersy C et al (2007) Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects. Allergy 62:1087–1090
14. Jin J, Liu X, Sun Y (2014) The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and lung function. Respir Res 15:130
15. Emmerich B, Emslander HP, Pachmann K et al (1990) Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom, on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 57:90–99
16. Fontanges R, Bottex C, Burckhart M, et al (1988) Broncho-Vaxom’s mechanism of action. Proc SEP Congr
17. Fontanges R, Bottex C, Cristau B et al (1990) Influence of a bacterial extract on antigen presentation and protection against experimental infections. Lung 168(Suppl):716–719
18. Grove A, Bergemann R, Keller R (1996) Preventive treatment of chronic bronchitis: a cost-effectiveness analysis for an immunoactive bacterial extract in Switzerland. Brit J Med Econom 10:1–14
19. Gutierrez-Tarango MD, Berber A (2001) Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest 119:1742–1748
20. Karaca NE, Gulez N, Aksu G et al (2011) Does OM-85 BV prophylaxis trigger autoimmunity in IgA deficient children? Int Immunopharmacol 11:1747–1751
21. Lusuardi M, Capelli A, Carli S et al (1993) Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest 103:1783–1791
22. Messerli C, Michetti F, Sauser-Hall P et al (1981) Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Rev Med Suisse Romande 101:143–146
23. Schaad UB, Mutterlein R, Goffin H (2002) Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest 122:2042–2049
24. Soler M, Mutterlein R, Cozma G (2007) Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 74:26–32
25. Heintz B, Schlenter WW, Kirsten R et al (1989) Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis–a multi-centric, placebo-controlled, double-blind study. Int J Clin Pharmacol Ther Toxicol 27:530–534
26. Paupe J (1991) Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration 58:150–154
27. Schaad UB (2010) OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr 6:5–12
28. Steurer-Stey C, Bachmann LM, Steurer J et al (2004) Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 126:1645–1655
29. Dougherty RH, Fahy JV (2009) Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 39:193–202
30. Pawankar R, Canonica GW, Holgate ST et al (2013) WAO White Book on Allergy: Update 2013. World Allergy Organization http://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf
31. Wedzicha JA, Donaldson GC (2003) Exacerbations of chronic obstructive pulmonary disease. Respir Care 48:1204–1213
32. GOLD (2013) Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) http://www.goldcopd.org/
33. MRC (1966) Instructions for use on the questionnaire on respiratory symptoms. Medical Research Council Committee on Research into Chronic Bronchitis Devon: W.J.Holman
34. Nicholson KG, Kent J, Ireland DC (1993) Respiratory viruses and exacerbations of asthma in adults. BMJ 307:982–986
35. Pattemore PK, Johnston SL, Bardin PG (1992) Viruses as precipitants of asthma symptoms. I. Epidemiology. Clin Exp Allergy 22:325–336
36. Stark JM, Busse WW (1991) Respiratory virus infection and airway hyperreactivity in children. Pediatr Allergy Immunol 2:95–110
37. Kline JN (2000) Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol 247:211–225
38. Szeto C, Gillespie KM, Mathieson PW (2000) Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 100:217–224
39. Lusuardi M (2004) Challenging mucosal immunity with bacterial extracts to prevent respiratory infections: an old therapy revisited. Monaldi Arch Chest Dis 61:4–5
40. Puigdollers JM, Serna GR, Hernandez del Rey I et al (1980) Immunoglobulin production in man stimulated by an orally administered bacterial lysate. Respiration 40:142–149
41. Roberton DM, Colgan T, Ferrante A et al (1990) IgG subclass concentrations in absolute, partial and transient IgA deficiency in childhood. Pediatr Infect Dis J 9:S41–S45
42. Lopez-Hoyos M (2010) Estandarización de IgE específica. Documento consenso del comité de Inmunología Clínica de la SEAIC